Rare disease focus PerkinElmer Genomics specializes in genetic and genomic testing for rare diseases, hereditary cancer, inherited conditions, and newborn screening, offering a broad care continuum from preconception to adult. Sales opportunity: position comprehensive omics panels and newborn screening capabilities to hospitals, clinics, and payer-driven registries seeking end-to-end diagnostic solutions.

Rapid sequencing expansion Recent initiatives include ultrarapid whole genome sequencing (urWGS) and expanded in vivo imaging to support fast diagnostics and research; these capabilities can be bundled with clinical decision support and rapid turnaround services to emergency and neonatal care providers.

Strategic collaborations Historical partnerships with Helix and WIH illustrate a pattern of co-development and validation studies; leverage these success stories to engage health systems and academic centers in joint research, validation programs, and pricing models that expand testing adoption.

Mid-market growth potential With revenue in the low tens of millions and a workforce of 5k–10k, there is room to target mid-sized hospitals, community labs, and regional genetics centers that seek scalable genomics services without engaging top-tier incumbents. Propose tiered offerings, managed services, and integrated data platforms.

Integrated tech stack Utilizes AWS, WordPress, Salesforce, and analytics tools, signaling capability for cloud-based data management, CRM-driven sales motion, and digital marketing optimization. Opportunity to upsell data integration, secure sharing, and workflow automation for a seamless clinician and lab user experience.